Neumora Therapeutics, Inc. (NasdaqGS: NMRA)
Health Care · Pharmaceuticals · US
$0.48
-4.84% today · -74.4% 1Y
Neumora Therapeutics, Inc. (NasdaqGS: NMRA) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $89.38M and employs 63 people.
Over the last twelve months the share price has lost 74.4%, trading between 0.45 and 3.65.
Tweenvest scores Neumora Therapeutics, Inc. across four factors: quality 35/100, value 29/100. Its strongest factor is quality.
NMRA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $89.38M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.22
- Dividend yield
- —
- Beta (5Y)
- 2.97
- 52-week high
- $3.65
- 52-week low
- $0.45
- Avg volume (3M)
- —
- Shares outstanding
- 187.90M
- Employees
- 63
- Next earnings
- —
About Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.
- ISIN
- US6409791000
- Founded
- 2019
- Listed since
- Sep 15, 2023
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Stella Pharma CorporationTSE: 4888 | $92.15M | ¥394.00 | -7.51% |
| Shree Ganesh Remedies LimitedBSE: 540737 | $90.37M | Rs681.25 | -1.72% |
| Renascience Inc.TSE: 4889 | $89.79M | ¥1,032.00 | -6.44% |
| Dong Sung Bio Pharm.Co.,Ltd.KOSE: A002210 | $89.60M | ₩1,283.00 | +0.39% |
| Dar Al Dawa Development and Investment Co. Ltd.ASE: DADI | $88.16M | JD1.25 | +1.63% |
| Hyphens Pharma International LimitedCatalist: 1J5 | $88.02M | S$0.37 | +2.82% |
| Kilitch Drugs (India) LimitedBSE: 524500 | $87.67M | Rs242.70 | +12.34% |
| HLS Therapeutics Inc.TSX: HLS | $87.26M | CA$4.09 | +5.68% |
Figures last refreshed Oct 11, 2026.